UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006863
Receipt number R000008020
Scientific Title A clinical study that investigates the ability of the HIRA-TAN to shorten the time required for the transition from an empiric therapy to a specific therapy in adult pneumonia.
Date of disclosure of the study information 2011/12/08
Last modified on 2015/06/09 23:02:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A clinical study that investigates the ability of the HIRA-TAN to shorten the time required for the transition from an empiric therapy to a specific therapy in adult pneumonia.

Acronym

Early initiation of specific therapy with HIRA-TAN

Scientific Title

A clinical study that investigates the ability of the HIRA-TAN to shorten the time required for the transition from an empiric therapy to a specific therapy in adult pneumonia.

Scientific Title:Acronym

Early initiation of specific therapy with HIRA-TAN

Region

Japan


Condition

Condition

pneumonia

Classification by specialty

Medicine in general Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Investigation on the ability of the HIRA-TAN to shorten the time required for the transition from an empiric therapy to a specific therapy

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Investigation on the ability of the HIRA-TAN to shorten the time required for the transition from an empiric therapy to a specific therapy.

Key secondary outcomes

Comparison of the overall performance of HIRA-TAN system and conventional method to identify the causative pathogen of pneumonia.
Comparison of the cost between HIRA-TAN system and conventional method required for identification of the casative pathogen of pneumonia.
Validity of the cutoff values that identify pathogenic roles of the commensal organisms in pneumonia; the organisms include S. pneumoniae, H. influenzae, M.catarrhalis, P. aeruginosa, A. baumannii, S. maltophilia, S. aureus, E. coli and S.marcescens.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

All inpatient and outpatient with pneumonia (aged 18 and older) who fulfill the criteria 1-4 and provid sputum classified as Miller and Jones M2, P1, P2 or P3.

1. Gram stain and culture of expectorated sputum is submitted before the treatment.
2. Urine antigen test for S. pneumoniae is submitted.
3. Blood sample for bacterial culture and Urine antigen test for L. pneumophila are submitted(cases that admit to the hospital only).
4. Influenza antigen test is submitted(flu season only).

Key exclusion criteria

Patients that do not fulfill the inclusion criteria.

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takashi Hirama

Organization

Saitama Medical University

Division name

Respiratory Medicine

Zip code


Address

38 Morohongo Moroyama Saitama 350-0495 Japan

TEL

+81-49-276-1319

Email

mycobacteriumtuberculosis@hotmail.com


Public contact

Name of contact person

1st name
Middle name
Last name Takashi Hirama

Organization

Saitama Medical University

Division name

Respiratory medicine

Zip code


Address

38 Morohongo Moroyama Saitama 350-0495 Japan

TEL

+81-49-276-1319

Homepage URL

http://hira-tan.com

Email

mycobacteriumtuberculosis@hotmail.com


Sponsor or person

Institute

Department of Respiratory Medicine
Saitama Medical University

Institute

Department

Personal name



Funding Source

Organization

Japan Society for the Promotion of Science(JSPS), Grant-in-Aid for Young Scientists(B)

Organization

Division

Category of Funding Organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)

Adaptable and Seamless Technology Transfer Program through Target-driven R&D from Japan Science and Technology Agency


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

埼玉医科大学病院(埼玉県),埼玉医科大学国際医療センター(埼玉県),関越病院(埼玉県),池の台病院(埼玉県),毛呂病院(埼玉県),ミオ医院(神奈川県),武蔵台病院(埼玉県),入間台クリニック(埼玉県),大野クリニック(埼玉県),気仙沼市立病院(宮城県)


Other administrative information

Date of disclosure of the study information

2011 Year 12 Month 08 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 12 Month 05 Day

Date of IRB


Anticipated trial start date

2011 Year 12 Month 01 Day

Last follow-up date

2015 Year 06 Month 09 Day

Date of closure to data entry

2015 Year 06 Month 09 Day

Date trial data considered complete

2015 Year 06 Month 09 Day

Date analysis concluded

2015 Year 06 Month 09 Day


Other

Other related information

We developed a new PCR-based diagnostic test for the pneumonia. We call it HIRA-TAN; it's abbreviation: Human cell controlled Identification of Respiratory Agent from TAN, which stands for sputum in Japanese.

The most prominent feature of the HIRA-TAN is its ability to differentiate therapeutic target and non-therapeutic target for commensal organism (The Japanese Patent (Patent No.4665203) obtained and PCT/JP2009/053976 pending).

HIRA-TAN combines the PCR system using cutoff value to discriminate the therapeutic target for commensal organism with the PCR system for non-commensal organism where the detected organism is concluded to be a causative pathogen (Hirama T, et al. PLoS One. 2011; 6(9): e24474).

That's why HIRA-TAN is a PCR-based comprehensive test by sputum and sensitive and rapid one, requiring within 4 h to complete.


Management information

Registered date

2011 Year 12 Month 08 Day

Last modified on

2015 Year 06 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008020


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name